(19)
(11) EP 4 100 061 A1

(12)

(43) Date of publication:
14.12.2022 Bulletin 2022/50

(21) Application number: 21750128.7

(22) Date of filing: 05.02.2021
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
A61K 31/352(2006.01)
 A61K 31/4747(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/497; A61P 35/00; A61K 45/06; A61K 31/675; A61K 31/704; A61K 31/573; A61K 31/475; G01N 33/5011; G01N 33/574; G01N 2800/52; A61K 38/00
 
C-Sets:
  1. A61K 31/475, A61K 2300/00;
  2. A61K 31/497, A61K 2300/00;
  3. A61K 31/675, A61K 2300/00;
  4. A61K 31/704, A61K 2300/00;
  5. A61K 31/573, A61K 2300/00;
(86) International application number:
PCT/US2021/016861
(87) International publication number:
WO 2021/158947 (12.08.2021 Gazette 2021/32)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 07.02.2020 WO PCT/CN2020/074515

(71) Applicants:
  • Li, Xiang
    Haidian District, Beijing 100094 (CN)
  • Jiang, Chun
    Hillsborough, CA 94010 (US)
  • CHEN, Yiyou
    San Jose, CA 95120 (US)

(72) Inventors:
  • Li, Xiang
    Haidian District, Beijing 100094 (CN)
  • Jiang, Chun
    Hillsborough, CA 94010 (US)
  • CHEN, Yiyou
    San Jose, CA 95120 (US)

(74) Representative: Cooley (UK) LLP 
22 Bishopsgate
London EC2N 4BQ
London EC2N 4BQ (GB)

   


(54) COMBINATION THERAPIES AND BIOMARKERS FOR TREATING CANCER